Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Omeprazole - AstraZeneca/Mitsubishi Tanabe Pharma Corporation

X
Drug Profile

Omeprazole - AstraZeneca/Mitsubishi Tanabe Pharma Corporation

Alternative Names: Antra; Belmazol; Losec; Mopral; Nuclosina; Omepral; Omeprazole magnesium; Omeprazon; Prilosec; Ulzol

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Hassle Lakemedel; Mitsubishi Tanabe Pharma Corporation
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiulcers; Gastric antisecretories; Small molecules
  • Mechanism of Action Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Dyspepsia; Gastric ulcer; Gastritis; Gastro-oesophageal reflux; Helicobacter infections; Peptic ulcer; Zollinger-Ellison syndrome

Most Recent Events

  • 27 Jul 2022 Lacer has been acquired by Italfarmaco
  • 01 Oct 2019 Cheplapharm Arzneimittel acquires the global commercial rights, excluding China, Japan, USA and Mexico, for omeprazole and associated brands from AstraZeneca
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top